AVR-RD-05

N/A

Report date: 2024/05/15 20:00:35

Base Information

Drug NameAVR-RD-05

Drug Alias NameAVR-RD-05

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionIduronate-2-sulfatase gene transference

TargetsIduronate-2-sulfatase

Therapy Area/IndicationsMucopolysaccharidosis II

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Manchester

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Manchester

Inactive CompaniesAvrobio

Active IndicationsMucopolysaccharidosis II

Inactive IndicationsN/A

Other Information

ATC CodeN/A